SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May. 18, 2009-- Exelixis, Inc. (Nasdaq:EXEL) announced today that George Scangos, PhD, the company’s president and chief executive officer, will present at the JMP Securities Eighth Annual Research Conference at 1:30 p.m. EDT / 10:30 a.m. PDT on Wednesday, May 20, 2009. Dr. Scangos will discuss the company’s development pipeline and corporate strategy.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company’s web site at www.exelixis.com.

Source: Exelixis, Inc.

Exelixis, Inc.
Investor Contact:
Charles Butler, 650-837-7277
Executive Director,
Corporate Communications
cbutler@exelixis.com
Media Contact:
Soleil Maxwell Harrison, 650-837-7012
Senior Manager,
Corporate Communications
sharrison@exelixis.com